Comparative immunogenicity in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine

Coursaget, Pierre; Bringer, L.; Sarr, G.; Bourdil, C.; Fritzell, Bernard; Blondeau, Christine; Yvonnet, B; Chiron, J.P.; Jeannée, Emile; Guindo, S.; Diop-Mar, I.

doi:10.1016/0264-410x(92)90067-t

Cited by 13 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recombinant DNA-derived hepatitis B vaccines have been proven to induce a similar rate of anti-HBs seroconversion and protection against hepatitis B disease as the plasma-derived vaccine [Stevens et al, 1987;Just et al, 1988;Coursaget et al, 1992]. Otherwise, the higher immunogenicity, safety, efficacy of the recombinant DNA-derived hepatitis B vaccines than plasma-derived vaccine was reported by other researchers [Hayashi et al, 1988;Most et al, 1992;Soyletir et al, 1992].…”

Section: Discussionmentioning

confidence: 98%

Seroepidemiology of hepatitis A, B, C, and E viruses infection among preschool children in Taiwan

Lin

Chen

et al. 2005

Journal of Medical Virology

View full text Add to dashboard Cite

Taiwan was a hyperendemic area for hepatitis A and B viruses (HAV and HBV) infection before late 1980s. To study the seroprevalence of hepatitis A, B, C, and E viruses (HCV and HEV) infection among preschool children in Taiwan, a community‐based survey was carried out in 54 kindergartens in 10 urban areas, 10 rural areas, and 2 aboriginal areas randomly selected through stratified sampling. Serum specimens of 2,538 preschool children were screened for the hepatitis A, C, and E antibodies by a commercially available enzyme immunoassay and for HBV markers by radioimmunoassay methods. The multivariate‐adjusted odd ratios (OR) with their 95% confidence intervals (CI) were estimated through the multiple logistic regression analysis. Females had a statistically significantly higher HAV seroprevalence than males. The seroprevalence of HCV infection increased significantly with age. The larger the sibship size, the higher the seroprevalence of HBV infection. Aboriginal children had a significantly higher seroprevalence of HBV and HEV infection and lower seroprevalence of HCV infection than non‐aboriginal children. A significantly higher seroprevalence of HBV infection was found in rural children than urban children. There was no significant association between serostatus of HAV and HEV infection and between serostatus of HBV and HCV infection among preschool children in Taiwan. The poor environmental and hygienic conditions in the aboriginal areas might play a role in infection with HBV and HEV. J. Med. Virol. 78:18–23, 2006. © 2005 Wiley‐Liss, inc.

show abstract

Section: Discussionmentioning

confidence: 98%

Seroepidemiology of hepatitis A, B, C, and E viruses infection among preschool children in Taiwan

Lin

Chen

et al. 2005

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…The Hevac-B vaccine contained 1%-2% HBsAgM. In contrast, the Heptavax-B vaccine did not contain preS2 proteins due to a treatment step with proteases, which however did not interfere with HBsAg-specific antigenicity [118][119][120]. Similar serum-derived vaccines were then produced from various manufacturers, such as Hepavax-B (Green Cross, Korea), Hepaccine-B (Cheil, Korea), and GCC VAC (Green Cross Corporation, Osaka) ( Table 1).…”

Section: The First Vaccine Generation Against Hbv: Vaccine Derived Frmentioning

confidence: 99%

“…With the availability of mammalian cell culture technologies, recombinant hepatitis B vaccines composed of SVPs have been developed containing the HBsAgS and HBsAgM (GenHevacB, Sanofi Pasteur Vaccins) and the additional HBsAgL subunits (Sci-B-Vac, VBI Vaccines; Hepacare, Medeva Pharma) ( Table 1). Chinese hamster ovary (CHO) cells (GenHevacB, Sci-B-Vac) [120,136] or murine cells (C1271) (Hepacare, Medeva Pharma) [137] were used to generate the vaccines. The GenHevac B vaccine is composed of HBsAgS/HBsAgM SVPs at a ratio 80:20, and compared in a clinical setting to the human plasma-derived Hevac B vaccine, both vaccines induced antibodies to the HBsAg in >90% of the participants (497 persons in the age range of 18-40 years).…”

Section: Third Generation Vaccine Concepts Against Hbvmentioning

confidence: 99%

“…The GenHevac B vaccine is composed of HBsAgS/HBsAgM SVPs at a ratio 80:20, and compared in a clinical setting to the human plasma-derived Hevac B vaccine, both vaccines induced antibodies to the HBsAg in >90% of the participants (497 persons in the age range of 18-40 years). Compared to the plasma-derived vaccine, the recombinant vaccine produced early and high levels of anti-preS2 antibodies, which may provide an additional advantage in prevention of a HBV infection [120,185].…”

Section: Third Generation Vaccine Concepts Against Hbvmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms

Jeevan-Raj

Netter

2020

Viruses

View full text Add to dashboard Cite

Hepatitis B remains one of the major global health problems more than 40 years after the identification of human hepatitis B virus (HBV) as the causative agent. A critical turning point in combating this virus was the development of a preventative vaccine composed of the HBV surface (envelope) protein (HBsAg) to reduce the risk of new infections. The isolation of HBsAg sub-viral particles (SVPs) from the blood of asymptomatic HBV carriers as antigens for the first-generation vaccines, followed by the development of recombinant HBsAg SVPs produced in yeast as the antigenic components of the second-generation vaccines, represent landmark advancements in biotechnology and medicine. The ability of the HBsAg SVPs to accept and present foreign antigenic sequences provides the basis of a chimeric particulate delivery platform, and resulted in the development of a vaccine against malaria (RTS,S/AS01, MosquirixTM), and various preclinical vaccine candidates to overcome infectious diseases for which there are no effective vaccines. Biomedical modifications of the HBsAg subunits allowed the identification of strategies to enhance the HBsAg SVP immunogenicity to build potent vaccines for preventative and possibly therapeutic applications. The review provides an overview of the formation and assembly of the HBsAg SVPs and highlights the utilization of the particles in key effective vaccines.

show abstract

“…It is as yet not established whether the enhanced immunogenicity of the Pre S1-Pre S2-S vaccine, as compared with S vaccines, is related to the presence of Pre S1 and/or Pre S2 antigen in the final vaccine preparation, or whether the unique composition of the CHOderived particles contributes to the immune response against HBV. Both yeast and CHO-derived vaccines containing Pre S2 particles have been reported to be more immunogenic than conventional non-glycosylated S vaccines [18][19][20].…”

Section: Discussionmentioning

confidence: 99%

Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report

Hourvitz

Mosseri

Solomon

et al. 1996

Journal of Viral Hepatitis

View full text Add to dashboard Cite

A new vaccine against hepatitis B virus (HBV) infection, produced in mammalian Chinese hamster ovary (CHO) cells, contains the small(s), middle (Pre S2) and large (Pre S1) surface proteins of HBV. Three injections of a 5-micrograms or 10-micrograms dose were administered intramuscularly (i.m.) at 0, 1 and 6 months to a group of 105 young adults, who were monitored for a period of 6 months after the third injection. Seroconversion rates were 100% after the second injection of the 5-micrograms or 10-micrograms dose. Geometric mean titres of HBsAb at 1 month after the third injection were 12,156 mIU ml-1 and 13,482 mIU ml-1 in those receiving the 5-micrograms and 10-micrograms dose respectively. The vaccine was well tolerated with no significant adverse events. These preliminary results suggest that the Pre S-s recombinant vaccine, produced in mammalian cells, is highly immunogenic, leading to 100% seroconversion in the population tested after injection of only two doses of 5 micrograms.

show abstract

Comparative immunogenicity in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine

Cited by 13 publications

References 10 publications

Seroepidemiology of hepatitis A, B, C, and E viruses infection among preschool children in Taiwan

Seroepidemiology of hepatitis A, B, C, and E viruses infection among preschool children in Taiwan

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms

Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report

Contact Info

Product

Resources

About